IQVIA (NYSE:IQV) Given New $210.00 Price Target at Mizuho

IQVIA (NYSE:IQV - Free Report) had its price objective trimmed by Mizuho from $242.00 to $210.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an outperform rating on the medical research company's stock.

Several other equities research analysts also recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Barclays dropped their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Stock Up 2.4 %

Shares of IQV traded up $3.45 during mid-day trading on Wednesday, reaching $149.00. The company had a trading volume of 850,980 shares, compared to its average volume of 1,382,233. The firm has a 50-day moving average price of $182.32 and a 200 day moving average price of $199.38. The company has a market capitalization of $26.27 billion, a price-to-earnings ratio of 19.87, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts forecast that IQVIA will post 10.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after purchasing an additional 50 shares during the period. Howard Capital Management Inc. lifted its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after buying an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after buying an additional 56 shares during the last quarter. Cypress Wealth Services LLC grew its holdings in IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after acquiring an additional 57 shares during the period. Finally, Harbor Investment Advisory LLC lifted its holdings in IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after acquiring an additional 58 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.